All you need to know in one place
Windsor, CT, November 1, 2022– SCA Pharma, a nationally recognized leader in the 503B compounded pharmaceuticals outsourcing industry, providing quality, service, and value to hospitals nationwide, has announced today that Vizient has awarded a multi-year agreement to the company for its full range of 503B ready-to-use products. Vizient is one of the nation’s leading health…
SCA Pharma, a nationally recognized leader in the 503B compounding pharmaceuticals outsourcing industry providing quality, service, and value to hospitals nationwide, has announced today the addition of Louis Pace as Chief Financial Officer and Chief Information Officer. Pace brings over 30 years of experience serving several successful private equity backed businesses in functional and P&L…
On January 27, 2022, the FDA announced its decision to not include Glycopyrrolate on the 503B bulks list. Following this announcement, outsourcing facilities will not be permitted to compound the drug-using bulk API, unless the product appears in the future on the FDA’s drug shortage list. Glycopyrrolate is not currently on the drug shortage list.…
SCA Pharma, which provides high-quality sterile admixture services to hospitals and health-care facilities nationwide, has named Scott Luce as Chief Executive Officer.
SCA Pharma is proud to honor these essential front-line providers during National Nurses Month.
Reflecting its unequivocal commitment to leading the 503B compounded pharmaceuticals outsourcing industry in excellence, SCA Pharmaceuticals has named Abby Kaplan as General Counsel and Chief Compliance Officer.
In our ongoing effort to enhance our customers’ experience, SCA Pharma has responded to feedback and made several changes to the customer portal. Here are recent updates: On the home page, customers will find previously published communications, providing easy access to this information. A new interactive catalog is now available by clicking on the SCA…
SCA Pharmaceuticals continues its aggressive expansion and implementation of growth strategies, and in doing so, has appointed Joe Akers as Chief Operating Officer.
WINDSOR, CONN. (Jan. 28, 2021)– SCA Pharmaceuticals, LLC, announced details last week of their acquisition by The Vistria Group and Excellere. Continuing their strategic growth initiatives, SCA Pharma is announcing the appointment of Mr. Scott Luce as Chief Commercial Officer. Mr. Luce will provide leadership and oversight of commercial operations as SCA Pharma continues to…
WINDSOR, CONN. (Jan. 21, 2021) – SCA Pharmaceuticals, LLC (“SCA Pharma”), has entered into a definitive membership interest purchase agreement with The Vistria Group (“Vistria”) and Excellere Partners (“Excellere”). The Vistria Group and Excellere Partners have purchased all of the issued and outstanding equity interests of SCA Pharma. The terms of the transaction were not…